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LETTERS TO THE EDITOR
Long-Standing Debate
on Cisplatin- Versus
Carboplatin-Based
Chemotherapy in the
Treatment of Advanced
Non-small Cell
Lung Cancer
To the Editor:
In the treatment of advanced non-
small cell lung cancer (NSCLC), cispla-
tin-based chemotherapy has a significant
impact on survival, as reported in a large
meta-analysis.1 The standard chemo-
therapy regimen is a doublet of cisplatin
plus one of the new agents.2 However,
cisplatin traditionally has serious toxic-
ities, which have prompted a worldwide
search for cisplatin analogues with a
better therapeutic index. Among them,
only carboplatin fulfilled all require-
ments for marketing approval; its neph-
rotoxicity, neuropathy, and gastrointes-
tinal toxicities were milder than those
of cisplatin.3 To date, there are eight
randomized trials addressing the issue
of cisplatin/carboplatin combined with
other cytotoxic agents. However, the re-
sults of these trials are conflicting; cis-
platin-based chemotherapy was superior
to carboplatin-based chemotherapy in
terms of survival in several trials,
whereas the other showed a significant
survival advantage of carboplatin-based
chemotherapy. Thus, the choice of cis-
platin or carboplatin has been a point of
controversy and, consequently, possible
equivalency in efficacy, its superior tox-
icity profiles, and convenience of ad-
ministration led to the predominant role
of carboplatin in the marketplace for the
treatment of advanced NSCLC.
To clarify this conflicting issue,
we first conducted a meta-analysis using
abstracted data.4 The analysis revealed
that the objective response rate was
higher in those with cisplatin-based che-
motherapy but without any statistically
significant survival advantage (hazard
ratio [HR], 1.050; 95% confidence inter-
val [CI], 0.907–1.216; p  0.515). Sub-
group analysis revealed that combina-
tion chemotherapy of cisplatin-based
chemotherapy yielded a longer survival
when combined with new agents (HR,
1.106; 95%CI, 1.005–1.218; p 0.039).
More recently, an individual patient da-
ta-based meta-analysis confirmed our
data with a quite consistent result (HR,
1.07; 95%CI, 0.99–1.15; p  0.101 and
HR, 1.11; 95%CI, 1.01–1.21; p 
0.026).5 These data indicate that cispla-
tin is superior to carboplatin in terms of
overall survival, especially when com-
bined with new cytotoxic agents such as
docetaxel, paclitaxel, and gemcitabine.
What can we conclude from this
information? Is there a clinically signif-
icant difference between cisplatin-based
regimens and carboplatin-based regi-
mens? It seems that the answer should
be “yes” in terms of overall survival,
and cisplatin should remain the key
agent for patients with a good perfor-
mance status. However, the survival dif-
ference is modest. Additionally, we
should take into account other clinical
parameters; for example, toxicity pro-
files are quite different between the two
treatment strategies.4,5 Cisplatin admin-
istration also usually requires a rather
complex and time-consuming procedure
compared with carboplatin. None of
these situations should be taken to mean
that carboplatin no longer has any role in
the management of advanced diseases,
when all of this information is applied to
daily clinical practice. An appropriate
treatment strategy should be considered
at an individual patient level, taking into
consideration not only the major end
point, overall survival, but also all these
other parameters.
Finally, the outcome of patients
with metastatic NSCLC is poor, regard-
less of whether they are treated with cis-
platin- or carboplatin-based regimens.
Many clinical trials have indicated no fur-
ther improvement in treatment outcome
with the existing chemotherapeutic agents.
We still need to continue to take advan-
tage of the recent advances we have made
in the understanding of basic tumor biol-
ogy to produce better treatment options.
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To the Editor:
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epidermal growth factor receptor
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(EGFR) tyrosine kinase inhibitor, in a
phase III randomized study versus pla-
cebo, prolonged survival in patients af-
fected by advanced non-small cell lung
cancer (NSCLC) previously treated with
one or two chemotherapy regimens.1
More than 50% of cases of ad-
vanced NSCLC are diagnosed in pa-
tients older than the age of 65 years.2
Concomitant diseases that may signifi-
cantly affect functional status, general
health, and tumor symptoms are fre-
quently present in this patient popula-
tion.3 Most patients at the time of recur-
rence of NSCLC have suffered some
types of toxicity from previous chemo-
therapy or comorbidities such as chronic
renal failure, contraindicating any chemo-
therapy. Erlotinib is one of the most prom-
ising agents in such patients because of its
favorable toxicity profile, efficacy, and the
possibility of oral administration.
Within a compassionate use pro-
gram, three advanced NSCLC pa-
tients, unsuitable for chemotherapy
because of chronic renal failure, re-
ceived oral erlotinib at the dose of 150
mg/day. Patients gave a written in-
formed consent.
Case 1: A 66-year-old woman,
never smoker, was diagnosed with stage
IIIB lung adenocarcinoma. Eastern Coop-
erative Oncology Group (ECOG) perfor-
mance status (PS) was 1. After six cycles
of a cisplatin plus gemcitabine regimen, a
partial response was achieved. She under-
went a right superior lung lobectomy plus
mediastinal lymph nodes dissection and
sequential mediastinal adjuvant radiother-
apy. EGFR expression was not available.
A few months after surgery, she devel-
oped brain metastases and received
whole-brain radiotherapy, achieving a
partial response. In the meanwhile, she
developed chronic renal failure, and
with a PS 2, she started treatment with
erlotinib. The baseline creatinine clear-
ance (CC) was 28 ml/min (serum creat-
inine level of 1.87 mg/dl) according to
the Cockroft and Gault formula.4 Renal
function was checked twice weekly,
with a CC ranging between 25 and 28
ml/min (serum creatinine levels between
2.02 and 1.87 mg/dl).
Case 2: A 62-year-old man, cur-
rent smoker, PS 1, developed a lung
adenocarcinoma stage IV for bone me-
tastasis. He received palliative radio-
therapy to the ninth dorsal vertebra and
then three cycles of a cisplatin plus gem-
citabine regimen but developed a bone
progression and mild chronic renal fail-
ure. He started treatment with pem-
etrexed for six cycles, reporting a stable
disease. EGFR expression, detected by
immunohistochemistry, was positive at
diagnosis. Due to a disease progression,
with a PS 2, he received erlotinib with a
baseline CC of 37.42 ml/min (serum
creatinine level of 2.2 mg/dl). Renal
function was checked twice weekly,
with CC ranging between 34.3 and 41.1
ml/min (serum creatinine levels between
2.4 and 2.0 mg/dl).
Case 3: A 76-year-old man, never
smoker, PS 2, was diagnosed with
stage IV squamous lung carcinoma due
to lung and adrenal metastases. He suf-
fered from an uncontrolled cough.
EGFR expression was not available. The
patient suffered from chronic renal fail-
ure (serum creatinine level 3.0 mg/dl
and CC 28.2 ml/min), contraindicating
chemotherapy. He started erlotinib. Re-
nal function was checked twice weekly,
with CC ranging between 28.0 and 34.2
ml/min (serum creatinine levels between
3.2 and 2.7 mg/dl).
At the cutoff date of September
30, 2006, these three patients are still on
treatment, achieving stable disease and
improving their disease-related symp-
toms and their PS to 1 (Table 1).
In these three patients, the
choice of erlotinib was based on the
need for palliative treatment, on drug
pharmacokinetics, and on its favorable
toxicity profile. Further renal function
was not impaired by therapy with er-
lotinib, and no severe toxicity was
recorded. Erlotinib is metabolized in
the liver, mainly by the cytochrome
P-450 isoenzyme CYP 3A4 (approxi-
mately 80%) and, to a lesser extent, by
hepatic CYP1A2 and pulmonary iso-
form CYP1A1. Erlotinib and its metab-
olites are excreted predominantly via the
feces, with renal elimination of drug and
metabolites accounting for less than 9% of
the administered dose.5
To the best of our knowledge, this
is the first report in which erlotinib was
administered in patients with chronic
renal failure achieving disease control.
In our opinion, these experiences justify TA
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further evaluation of erlotinib in a larger
sample of patients with advanced NSCLC
affected by chronic renal failure.
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